97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience

Abstract

lectures and ad boards paid to institute: AbbVie; Honoraria (institution), honoraria for lectures and ad boards paid to institute: Celgene; Honoraria (institution), honorarium for lectures paid to institute: PriME/Medscape; Honoraria (self), lecture: Chugai; Honoraria (self), Honoraria (institution), honoraria paid to institute: Daiichi Sankyo; Honoraria (institution), honorarium for ad boards paid to institute: Lilly; Honoraria (institution), advisor honorarium paid to institute: BMS; Honoraria (institution), advisor honorarium paid to institute: Puma; Honoraria (institution), paid to institute: Immunomedics; Honoraria (institution), honorarium for lectures and ad boards paid to institute: AstraZeneca; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Pierre Fabre; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Merck; Honoraria (institution), advisor honorarium paid to institute: EirGenix; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Amgen; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Novartis; Honoraria (institution), honorarium for lectures and ad boards paid to institute: Pfizer; Honoraria (institution), grant and honorarium paid to institute: Roche; Honoraria (institution), paid to institute:

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer

“…Some studies have suggested that CDK4/6 inhibitor treatment could impair patients’ immune responses, 29 , 30 while others have suggested that CDK4/6 inhibitor use is safe during the pandemic. 31 , 32 Recently, Zagouri and colleagues conducted a study of 21 patients with breast cancer on CDK4/6 inhibitors and demonstrated that these patients had a similar immune response as healthy controls. 33 In our study, we obtained similar results with an expanded patient cohort ( N = 64).…”